bpc 157 gastroparesis Stable gastric pentadecapeptide in the treatment of colitis and ischemia and reperfusion in rats: New insights BPC-157 Rapid | Fullscript

doi: 10.1007/s00441-019-03016-8

Studies have demonstrated that Semaglutide reduces appetite, improves control of eating, and reduces food cravings in addition to improving glycemic control

Oliviero F, Scanu A, Zamudio-Cuevas Y, Punzi L, Spinella P

It reflects the combined stability data for the peptide itself and the preservative activity of the benzyl alcohol in bacteriostatic water

BPC-157 is better suited for chronic tendon injuries, gut healing, and situations where you want daily sustained signaling at a lower cost ($250/mo)

Reported Side Effects in Experimental Models In preclinical literature, BPC-157 has demonstrated a strong safety profile in rodent models